About Repare Therapeutics
Repare Therapeutics is a publicly listed company based in Montreal (Canada) founded in 2016 by Daniel Durocher, Agnel sfeir, and Frank Sicheri, and was acquired by Alexis Bio in November 2025. It operates as a targeted cancer therapies for genetic tumor alterations are developed. Repare Therapeutics has raised $165.5 million across 3 funding rounds from investors including TD Securities, Orbimed and Celgene. The company has 129 employees. Repare Therapeutics offers products and services including RP-3467, RP-1664, Lunresertib, and Camonsertib. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Precision Medicine. Its competitors include Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines and 1 more; 6 of its 6 listed competitors have raised funding.
Company details
Repare Therapeutics was founded in 2016 in Montreal, Canada, within the biotechnology sector. Targeted therapies addressing genetic alterations in selected tumors are developed using a genome-wide, CRISPR-enabled SNIPRx platform. This approach systematically identifies cancer treatments focused on genomic instability, such as DNA damage repair. The lead candidate, PolQ, inhibits Polθ to target tumors with mutations in homology-directed repair genes. Operations emphasize precision oncology for oncology applications.
- Headquarters Montreal, Canada
- Employees 129
- Founders Daniel Durocher, Agnel sfeir, Frank Sicheri
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website reparerx.com
- Social LinkedIn X
- Acquired by Alexis Bio (Nov 2025)
- Legal Name Repare Therapeutics Inc.
- Annual Revenue$53.48 M (USD)4.58as on Dec 31, 2024
- Net Profit-$84.69 M (USD)9.71as on Dec 31, 2024
- EBITDA-$89.29 M (USD)20.85as on Dec 31, 2024
- Total Equity Funding$165.5M (USD)
in 3 rounds
- Latest Funding Round$15M (USD), Series B
May 2020
- InvestorsTD Securities
& 11 more
- Employee Count129
- Acquired byAlexis Bio
(Nov 2025)
Products & Services of Repare Therapeutics
Repare Therapeutics offers a comprehensive portfolio of products and services, including RP-3467, RP-1664, Lunresertib, and Camonsertib.
Inhibitor targeting Polθ ATPase for cancer treatment
Inhibitor for PLK4 in oncology applications
PKMYTI inhibitor for cancer therapy development
ATR inhibitor used in precision oncology trials
Funding Insights of Repare Therapeutics
Repare Therapeutics has successfully raised a total of $165.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $15 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $165.5M
- Total Rounds 3
- Last Round Series B — $15M
- First Round $68M
(Jun 2017)
- Investors Count 11
All 3 funding rounds of Repare Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $15M | Series B | – | Bristol-Myers Squibb | – |
| Sep 2019 | $82.5M | Series B | – | Cowen | |
| Jun 2017 | $68M | Series A | – | MPM Capital, Versant Ventures |
12 investors in total: 12 institutional.
Investors in Repare Therapeutics
Repare Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include TD Securities, Orbimed and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
US private equity investments are managed by BVF Partners. | – | bvflp.com | San Francisco, United States | |
Private equity fund focused on the biotechnology sector | – | logoscapital.com | San Francisco, United States | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | – | versantventures.com | - | |
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States | |
Invests in biotech firms developing life-saving drugs and technologies. | – | mpmcapital.com | - | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Commercial banking services for small and medium-sized enterprises are provided. | 1944 | bdc.ca | Montreal, Canada | |
Offers savings plans, investments, and financing for businesses and individuals. | 1983 | fondsftq.com | Montreal, Canada |
Investor details for Repare Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Repare Therapeutics
24 people are tracked at Repare Therapeutics (11 in leadership, 7 in board & advisors, 6 in team); the tracked headcount is 129.
| Name | Role | Group |
|---|---|---|
Daniel Durocher | Co-Founder | Leadership |
Agnel sfeir | Co-Founder | Leadership |
Frank Sicheri | Co-Founder | Leadership |
Stephanie Guerrera | Vice President, Project Leader And PMO Head | Leadership |
Philip Herman | EVP, Chief Commercial & Portfolio Development Officer | Leadership |
Steve Forte | EVP & CFO | Leadership |
Christopher Kendall Ph. D. | VP Of Finance And Fp&a | Leadership |
Zhizi Zhao | Vp, Information Technology | Leadership |
Sandra Alves Cpa, Ca | Senior VP Finance & Chief Accounting Officer | Leadership |
Yousry E. | Executive Director Head Of SOX Compliance | Leadership |
Angelos Dovletoglou | Senior Vice President Of Technical Operations | Leadership |
David Bonita | Director | Board & advisors |
Ann D. Rhoads | Director | Board & advisors |
Sam Kulkarni | Director | Board & advisors |
Briggs W. Morrison | Director | Board & advisors |
Thomas Civik | Chairman | Board & advisors |
Todd Foley | Director | Board & advisors |
Carol A. Schafer | Director | Board & advisors |
Adisa Profka | Financial And Payable Analyst | Team |
Autumn Jarrett | IT Support Specialist | Team |
4 more people are available in the full profile.
Complete people profiles for Repare Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Repare Therapeutics
Repare Therapeutics is a publicly listed company on the NASDAQ with ticker symbol RPTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Jun 2020
- Listed onNASDAQ: RPTX
- Listed entityRepare Therapeutics Inc.
- Exchange sectorHealth technology
- ISINUS7602731025
- Share price$2.65 (+0.76% on the day) · 2026-01-29
- Market capitalisation$114.2M
- EPS (diluted, trailing year)$-1.69
- Volume (last session)1,219,919
- Analyst consensusStrong buy
Financials of Repare Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $53.5M | -$84.7M | -$89.3M |
| 2023 | $51.1M | -$93.8M | -$112.8M |
| 2022 | $131.8M | -$29.1M | -$14.2M |
| 2021 | $7.6M | -$106.9M | -$104.2M |
| 2020 | $135,000 | -$53.4M | -$51.6M |
Detailed financial statements for Repare Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Repare Therapeutics
5 dated milestones of Repare Therapeutics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Repare Therapeutics is founded.
- Funding First funding round of $68.0M.
- Funding Latest funding round, Series B, of $15.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Alexis Bio.
Competitors of Repare Therapeutics
Repare Therapeutics has 6 listed competitors in our database, 6 of them funded. They include Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Repare Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Repare Therapeutics
The website of Repare Therapeutics (reparerx.com) receives about 6.8K visits a month and ranks #3,355,053 among all websites worldwide, #4,396 in Biotechnology and Pharmaceuticals.
- Monthly visits6.8K
▲ 11.2% vs previous month
- Unique visitors2.6K
per month
- Global rank#3,355,053
among all websites
- Category rank#4,396
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.6
- Average visit17 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Repare Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| endpts.com | 100% | 8.4K | #3,077,209 | View details | |
| fiercebiotech.com | 80% | 858.3K | #81,022 | View details |
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Repare Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Repare Therapeutics
Complete news archive for Repare Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Repare Therapeutics
Repare Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Repare Therapeutics is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Repare Therapeutics is a funded company, having raised a total of $165.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $68M, raised on Jun 2017.
Repare Therapeutics has 129 employees.
Annual revenue of Repare Therapeutics is $53.48M as on Dec 31, 2024.
Repare Therapeutics was founded in 2016 in Montreal, Canada, within the biotechnology sector. Targeted therapies addressing genetic alterations in selected tumors are developed using a genome-wide, CRISPR-enabled SNIPRx platform. This approach systematically identifies cancer treatments focused on genomic instability, such as DNA damage repair. The lead candidate, PolQ, inhibits Polθ to target tumors with mutations in homology-directed repair genes. Operations emphasize precision oncology for oncology applications.
Repare Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Repare Therapeutics offers RP-3467, RP-1664, Lunresertib, and Camonsertib.
Yes, Repare Therapeutics is publicly traded on NASDAQ under the ticker symbol RPTX.
Repare Therapeutics has 12 investors. Key investors include TD Securities, Orbimed, Celgene, BDC, and Bristol-Myers Squibb.
Yes. Repare Therapeutics was acquired by Alexis Bio in November 2025.